S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice

K. Takeda, Nobuaki Miyahara, T. Kodama, C. Taube, A. Balhorn, A. Dakhama, K. Kitamura, A. Hirano, M. Tanimoto, E. W. Gelfand

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

S-carboxymethylcysteine (S-CMC) has been used as a mucoregulator in respiratory diseases. However, the mechanism of action of S-CMC on allergic airway inflammation has not yet been defined. In the present study, BALB/c mice were initially sensitised and challenged to ovalbumin (OVA) and, weeks later, re-challenged with OVA (secondary challenge). S-CMC (5-100 mg·kg-1) was administered from 2 days before the secondary challenge through to the day of assay. Mice developed airway hyperresponsiveness (AHR) 6 h after the secondary challenge and increased numbers of neutrophils were present in the bronchoalveolar lavage (BAL) fluid. At 72 h after secondary challenge, mice again developed AHR, but the BAL fluid contained large numbers of eosinophils. S-CMC treatment was found to reduce AHR and neutrophilia at 6 h, as well as eosinophilia and AHR at 72 h. These effects appeared to be dose dependent. Goblet cell hyperplasia, observed at 72 h, was reduced by S-CMC. In BAL fluid, increased levels of interferon-γ, interleukin (IL)-12 and IL-10 and decreased levels of IL-5 and IL-13 were detected. In conclusion, the data indicate that S-carboxymethylcysteine is effective in reducing airway hyperresponsiveness and airway inflammation at two distinct phases of the response to the secondary allergen challenge in sensitised mice. Copyright

Original languageEnglish
Pages (from-to)577-585
Number of pages9
JournalEuropean Respiratory Journal
Volume26
Issue number4
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Carbocysteine
Bronchoalveolar Lavage Fluid
Ovalbumin
Inflammation
Goblet Cells
Interleukin-13
Interleukin-5
Eosinophilia
Interleukin-12
Eosinophils
Interleukin-10
Allergens
Interferons
Hyperplasia
Neutrophils

Keywords

  • Airway hyperresponsiveness
  • Eosinophils
  • Neutrophils
  • S-carboxymethylcysteine

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice. / Takeda, K.; Miyahara, Nobuaki; Kodama, T.; Taube, C.; Balhorn, A.; Dakhama, A.; Kitamura, K.; Hirano, A.; Tanimoto, M.; Gelfand, E. W.

In: European Respiratory Journal, Vol. 26, No. 4, 10.2005, p. 577-585.

Research output: Contribution to journalArticle

Takeda, K, Miyahara, N, Kodama, T, Taube, C, Balhorn, A, Dakhama, A, Kitamura, K, Hirano, A, Tanimoto, M & Gelfand, EW 2005, 'S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice', European Respiratory Journal, vol. 26, no. 4, pp. 577-585. https://doi.org/10.1183/09031936.05.00090304
Takeda, K. ; Miyahara, Nobuaki ; Kodama, T. ; Taube, C. ; Balhorn, A. ; Dakhama, A. ; Kitamura, K. ; Hirano, A. ; Tanimoto, M. ; Gelfand, E. W. / S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice. In: European Respiratory Journal. 2005 ; Vol. 26, No. 4. pp. 577-585.
@article{16337010692941169fd0d6ea61ff1410,
title = "S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice",
abstract = "S-carboxymethylcysteine (S-CMC) has been used as a mucoregulator in respiratory diseases. However, the mechanism of action of S-CMC on allergic airway inflammation has not yet been defined. In the present study, BALB/c mice were initially sensitised and challenged to ovalbumin (OVA) and, weeks later, re-challenged with OVA (secondary challenge). S-CMC (5-100 mg·kg-1) was administered from 2 days before the secondary challenge through to the day of assay. Mice developed airway hyperresponsiveness (AHR) 6 h after the secondary challenge and increased numbers of neutrophils were present in the bronchoalveolar lavage (BAL) fluid. At 72 h after secondary challenge, mice again developed AHR, but the BAL fluid contained large numbers of eosinophils. S-CMC treatment was found to reduce AHR and neutrophilia at 6 h, as well as eosinophilia and AHR at 72 h. These effects appeared to be dose dependent. Goblet cell hyperplasia, observed at 72 h, was reduced by S-CMC. In BAL fluid, increased levels of interferon-γ, interleukin (IL)-12 and IL-10 and decreased levels of IL-5 and IL-13 were detected. In conclusion, the data indicate that S-carboxymethylcysteine is effective in reducing airway hyperresponsiveness and airway inflammation at two distinct phases of the response to the secondary allergen challenge in sensitised mice. Copyright",
keywords = "Airway hyperresponsiveness, Eosinophils, Neutrophils, S-carboxymethylcysteine",
author = "K. Takeda and Nobuaki Miyahara and T. Kodama and C. Taube and A. Balhorn and A. Dakhama and K. Kitamura and A. Hirano and M. Tanimoto and Gelfand, {E. W.}",
year = "2005",
month = "10",
doi = "10.1183/09031936.05.00090304",
language = "English",
volume = "26",
pages = "577--585",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

TY - JOUR

T1 - S-carboxymethylcysteine normalises airway responsiveness in sensitised and challenged mice

AU - Takeda, K.

AU - Miyahara, Nobuaki

AU - Kodama, T.

AU - Taube, C.

AU - Balhorn, A.

AU - Dakhama, A.

AU - Kitamura, K.

AU - Hirano, A.

AU - Tanimoto, M.

AU - Gelfand, E. W.

PY - 2005/10

Y1 - 2005/10

N2 - S-carboxymethylcysteine (S-CMC) has been used as a mucoregulator in respiratory diseases. However, the mechanism of action of S-CMC on allergic airway inflammation has not yet been defined. In the present study, BALB/c mice were initially sensitised and challenged to ovalbumin (OVA) and, weeks later, re-challenged with OVA (secondary challenge). S-CMC (5-100 mg·kg-1) was administered from 2 days before the secondary challenge through to the day of assay. Mice developed airway hyperresponsiveness (AHR) 6 h after the secondary challenge and increased numbers of neutrophils were present in the bronchoalveolar lavage (BAL) fluid. At 72 h after secondary challenge, mice again developed AHR, but the BAL fluid contained large numbers of eosinophils. S-CMC treatment was found to reduce AHR and neutrophilia at 6 h, as well as eosinophilia and AHR at 72 h. These effects appeared to be dose dependent. Goblet cell hyperplasia, observed at 72 h, was reduced by S-CMC. In BAL fluid, increased levels of interferon-γ, interleukin (IL)-12 and IL-10 and decreased levels of IL-5 and IL-13 were detected. In conclusion, the data indicate that S-carboxymethylcysteine is effective in reducing airway hyperresponsiveness and airway inflammation at two distinct phases of the response to the secondary allergen challenge in sensitised mice. Copyright

AB - S-carboxymethylcysteine (S-CMC) has been used as a mucoregulator in respiratory diseases. However, the mechanism of action of S-CMC on allergic airway inflammation has not yet been defined. In the present study, BALB/c mice were initially sensitised and challenged to ovalbumin (OVA) and, weeks later, re-challenged with OVA (secondary challenge). S-CMC (5-100 mg·kg-1) was administered from 2 days before the secondary challenge through to the day of assay. Mice developed airway hyperresponsiveness (AHR) 6 h after the secondary challenge and increased numbers of neutrophils were present in the bronchoalveolar lavage (BAL) fluid. At 72 h after secondary challenge, mice again developed AHR, but the BAL fluid contained large numbers of eosinophils. S-CMC treatment was found to reduce AHR and neutrophilia at 6 h, as well as eosinophilia and AHR at 72 h. These effects appeared to be dose dependent. Goblet cell hyperplasia, observed at 72 h, was reduced by S-CMC. In BAL fluid, increased levels of interferon-γ, interleukin (IL)-12 and IL-10 and decreased levels of IL-5 and IL-13 were detected. In conclusion, the data indicate that S-carboxymethylcysteine is effective in reducing airway hyperresponsiveness and airway inflammation at two distinct phases of the response to the secondary allergen challenge in sensitised mice. Copyright

KW - Airway hyperresponsiveness

KW - Eosinophils

KW - Neutrophils

KW - S-carboxymethylcysteine

UR - http://www.scopus.com/inward/record.url?scp=26844566658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844566658&partnerID=8YFLogxK

U2 - 10.1183/09031936.05.00090304

DO - 10.1183/09031936.05.00090304

M3 - Article

C2 - 16204586

AN - SCOPUS:26844566658

VL - 26

SP - 577

EP - 585

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 4

ER -